These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2401123)

  • 1. Comparison of the pharmacodynamic effects of intravenous and oral propafenone.
    Haefeli EW; Vozeh S; Ha HR; Follath F
    Clin Pharmacol Ther; 1990 Sep; 48(3):245-54. PubMed ID: 2401123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concentration-effect relations of 5-hydroxypropafenone in normal subjects.
    Haefeli WE; Vozeh S; Ha HR; Taeschner W; Follath F
    Am J Cardiol; 1991 May; 67(11):1022-6. PubMed ID: 2018005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic evaluation of propafenone in patients with ventricular arrhythmia. Propafenone Research Group.
    Zoble RG; Kirsten EB; Brewington J
    Clin Pharmacol Ther; 1989 May; 45(5):535-41. PubMed ID: 2721109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous and oral propafenone for treatment of tachycardia in infants and children: pharmacokinetics and clinical response.
    Ito S; Gow R; Verjee Z; Giesbrecht E; Dodo H; Freedom R; Tonn GR; Axelson JE; Zalzstein E; Rosenberg HC; Koren G
    J Clin Pharmacol; 1998 Jun; 38(6):496-501. PubMed ID: 9650538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man.
    Brode E; Müller-Peltzer H; Hollmann M
    Methods Find Exp Clin Pharmacol; 1988 Nov; 10(11):717-27. PubMed ID: 3221745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy.
    Capucci A; Boriani G; Marchesini B; Strocchi E; Tomasi L; Balducelli M; Frabetti L; Ambrosioni E; Magnani B
    Cardiovasc Drugs Ther; 1990 Feb; 4(1):281-7. PubMed ID: 2285622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.
    Labbé L; O'Hara G; Lefebvre M; Lessard E; Gilbert M; Adedoyin A; Champagne J; Hamelin B; Turgeon J
    Clin Pharmacol Ther; 2000 Jul; 68(1):44-57. PubMed ID: 10945315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine.
    Ujhelyi MR; O'Rangers EA; Fan C; Kluger J; Pharand C; Chow MS
    Clin Pharmacol Ther; 1993 Jan; 53(1):38-48. PubMed ID: 8422740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic interactions of propafenone and cimetidine.
    Pritchett EL; Smith WM; Kirsten EB
    J Clin Pharmacol; 1988 Jul; 28(7):619-24. PubMed ID: 3063727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonlinear kinetics of propafenone metabolites in healthy man.
    Vozeh S; Haefeli W; Ha HR; Vlcek J; Follath F
    Eur J Clin Pharmacol; 1990; 38(5):509-13. PubMed ID: 2379537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of propafenone on the parameters of body surface electrocardiogram in comparison with those of disopyramide].
    Omori I; Ochiai M; Inoue D; Asayama J; Nakagawa M
    Kokyu To Junkan; 1993 Jul; 41(7):647-52. PubMed ID: 8337528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of propafenone during acute and chronic administration.
    Giani P; Landolina M; Giudici V; Bianchini C; Ferrario G; Marchi S; Riva E; Latini R
    Eur J Clin Pharmacol; 1988; 34(2):187-94. PubMed ID: 3383990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Propafenone: a new antiarrhythmic agent.
    Chow MS; Lebsack C; Hilleman D
    Clin Pharm; 1988 Dec; 7(12):869-77. PubMed ID: 3061720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic characterization of the antiarrhythmic drug diprafenone in man.
    Trenk D; Wagner F; Sachs W; Jähnchen E
    Eur J Clin Pharmacol; 1989; 37(3):313-6. PubMed ID: 2612546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Significance of the degree of oxidative hepatic metabolism in conditioning the pharmacokinetics and the pharmacodynamics of propafenone].
    Boriani G; Capucci A; Strocchi E; Marchesini B; Baroni M; Frabetti L; Ambrosioni E; Magnani B
    G Ital Cardiol; 1991 May; 21(5):517-26. PubMed ID: 1936756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
    Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M
    Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.
    Funck-Brentano C; Kroemer HK; Pavlou H; Woosley RL; Roden DM
    Br J Clin Pharmacol; 1989 Apr; 27(4):435-44. PubMed ID: 2719900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.
    Harron DW; Brogden RN
    Drugs; 1987 Dec; 34(6):617-47. PubMed ID: 3322781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodialysis removal of propafenone.
    Burgess ED; Duff HJ
    Pharmacotherapy; 1989; 9(5):331-3. PubMed ID: 2813154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereoselective steady state disposition and action of propafenone in Chinese subjects.
    Li G; Gong PL; Qiu J; Zeng FD; Klotz U
    Br J Clin Pharmacol; 1998 Nov; 46(5):441-5. PubMed ID: 9833596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.